With it likely that Chugai will come in ahead of its FY24 full year revenue guidance, analyst Nia Dokova sees this as a potential catalyst for the stock. The recent -15% decline from its 28 Oct high provides an opportunity to accumulate shares of one of the few pharma plays in Japan with no patent cliff issues.
When the BoJ raised rates in March, it had been 17 years since it had last done so, though the world was very different then. While the July rate hike was unlikely to move the economic needle, the question now is what else might follow the subsequent financial market maelstrom. Pelham Smithers discusses the outlook for Japan’s macro environment, what new fiscal policies the new PM might introduce, how the BoJ might react and the all-important trend in corporate earnings. This then leads us to...
EQS-News: Olympus Corp. / Key word(s): Miscellaneous Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, India 12.06.2024 / 14:30 CET/CEST The issuer is solely responsible for the content of this announcement. Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, India Endoscopy Engineering support services in India Tokyo, Japan, 12 June 2024, JCN Newswire - Olympus Corporation (Olympus), a global MedTech Company committed to making people’s lives healthier, safer and more fulfilling, today announced its strategic initiative ...
Olympus (7733 JT) seems to be leaning into the market’s acceptance that FY23 is a write-off, reporting yet more expenses for Q4. This review includes management’s comments on how the firm plans to achieve an earnings recovery in FY24.
FY23 is proving to be a housecleaning year for Olympus, some of it undertaken proactively, such as the sale of the scientific instruments business, some of it reactively, such as recalls and write downs. Analyst Nia Dokova discusses the outlook.
In our 2010 Japan Perspective, written close to the nadir of the bear market, we discussed what was wrong with Japan, but also what it was starting to do right. Fourteen years on, the Nikkei 225 - though not yet Topix - has hit a new all-time high. This report looks at how Japan built on those things that were going right, while also starting to address what else needed to be done, and looks at whether more is needed to be done if the market rally is to continue from here.
Asset sale gains by Olympus in FY22 made it hard for FY23 to look good anyway, but a procession of problems has turned a difficult situation into a bad one. However, with most of the issues being one-offs, a recovery in earnings is expected in FY24. With the shares down -30% from their peak, it may be time to revisit the stock.
Whereas hydrogen fuel cell systems have not had a break-through in the passenger car market, the situation for the commercial vehicle market looks very different: For heavy-duty trucks in particular, FCVs are superior to BEVs when it comes to charging times, payload and driving range. In this report, analyst Julie Boote assesses the outlook for hydrogen fuel cell trucks and explains how the main global participants are positioned.
YAMATO HOLDINGS CO (JP), a company active in the Delivery Services industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation is now 2 out of 4 stars while its market behaviour can be considered as defensive. theScreener believes that the gain of a star(s) and an improvement in the market risk perception allows upgrading the general evaluation to Slightly Positive. As of the analysis date April 1, 2022, the closing price was JPY 2,...
The Japanese stock market is in an interesting phase where the Bank of Japan is supporting the bond market rather than the stock market. While this phase lasts, the dollar should remain above ¥120/$ and perhaps strengthen further against the yen. This report looks at what this phase might mean for the Japanese stock market as a whole, and for stock selection. The PSA Focus List has also been updated.
The independent financial analyst theScreener just awarded an improved star rating to TOKAI CARBON (JP), active in the Speciality Chemicals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date March 25, 2022, the closi...
The independent financial analyst theScreener just lowered the general evaluation of HOYA (JP), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date March 18, 2022, the closing price was JPY 13,800.00 and ...
The independent financial analyst theScreener just awarded an improved star rating to CHUGAI PHARM. (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date March 18, 2022, th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.